Kiadis Aims To Boost Stem Cell Transplant Market With Adjuvant Filing
Executive Summary
Kiadis Pharma hopes to tap into a $1bn-plus commercial opportunity with its lead product ATIR101 in the treatment of blood cancer. ATIR101 has just been filed in Europe on the strength of data from single dose Phase II trial; a Phase III trial to pursue US approval is ongoing.